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Background: There is limited information on risk factors for
treatment-related pneumonitis in esophageal cancer patients.
Aim of the Study: To determine factors associated with treatment-
related pneumonitis in esophageal cancer patients treated with de-
finitive chemoradiotherapy.
Materials and Methods: We retrospectively reviewed clinical data
from esophageal cancer patients treated with definitive chemoradio-
therapy from 2000 to 2003. Demographic, clinical, and treatment-
related data were collected for all patients. The time to occurrence of
grade 2 pneumonitis was calculated from the end of radiotherapy.
Univariate analyses were performed to determine the existence of
any association between patient demographic, clinical, or treatment
characteristics and pneumonitis.
Results: In total, 96 patients were included in the study with a
median follow-up of 8 months (range, 1–48 months). Among
them, 23 patients also received an average of two cycles of systemic
chemotherapy before the initiation of concurrent chemoradiation.
The incidence of grade 2 pneumonitis was 22% at 1 year. Sys-
temic chemotherapy before concurrent chemoradiation was signifi-
cantly associated with an increased risk of grade 2 pneumonitis
(p  0.003), with the 1-year incidence of grade 2 pneumonitis for
patients with and without systemic chemotherapy being 49 and 14%,
respectively. No other clinical or dosimetric factors investigated
were associated with the risk of grade 2 pneumonitis.
Conclusions: Systemic chemotherapy before concurrent chemora-
diation was significantly associated with an increased risk of grade
2 pneumonitis, suggesting that induction chemotherapy may have
sensitized the lung tissue to radiation damage in esophageal cancer
patients.
Key Words: Treatment-related pneumonitis, Esophageal cancer,
Radiotherapy, Concurrent chemotherapy, Systemic chemotherapy.
(J Thorac Oncol. 2008;3: 277–282)
Treatment-related pneumonitis (TRP) is one of the majoracute toxicities after thoracic irradiation. Many studies
have demonstrated that dosimetric factors, such as mean lung
dose1–8 and percentage volume of lung receiving more than a
threshold dose,2,9–13 are significant risk factors for TRP.
Among esophageal cancer patients, the reported crude inci-
dence of TRP has ranged from 3 to 11%.14–16 In a previous
study17 that included esophageal cancer patients treated with
preoperative concurrent chemoradiation followed by esoph-
agectomy, we found that the volume of lung spared from
radiation doses 5 Gy was the only factor significantly
associated with postoperative pulmonary complications, de-
fined as acute respiratory distress syndrome or pneumonia.
Nevertheless, there is very limited information in the litera-
ture on risk factors for TRP in patients with esophageal
cancer treated with definitive chemoradiation.
We therefore performed a retrospective investigation to
identify clinical and dosimetric factors predictive of TRP in
patients with a diagnosis of esophageal cancer who were
treated with definitive chemoradiation.
PATIENTS AND METHODS
Patients
We retrospectively reviewed the medical records of
patients with a diagnosis of esophageal cancer treated at our
institution from January 2000 to December 2003, after three-
dimensional conformal radiation (3D-CRT) become our stan-
dard of care. Patients were included in the present study if (1)
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they had newly diagnosed and pathologically confirmed
esophageal cancer that was treated with definitive chemother-
apy and 3D-CRT; (2) their dose-volume histograms (DVHs)
were available from institutional archives; and (3) radio-
graphic images and symptom assessments were available to
evaluate the occurrence of TRP. Patients were excluded if
they underwent thoracic irradiation before concurrent chemo-
therapy and 3D-CRT, had lung or esophageal surgery, or had
a treatment break with a duration of more than 5 days during
radiotherapy. This study was approved by our Institutional
Review Board as a retrospective chart review study and
informed consents were waived. Health Insurance Portability
and Accountability Act regulations were enforced.
Data Collection
The following data were collected from medical
records: demographic information (sex, age, and smoking
history), medical history (chronic obstructive pulmonary dis-
ease, diabetes, and Karnofsky performance status), disease
characteristics (histologic type, tumor location, and clinical
stage), radiographic images, symptom assessments, and treat-
ment-related factors (radiotherapy and chemotherapy regi-
mens and DVH parameters), occurrence and grade of TRP,
and duration of follow-up.
Treatment
The patients’ chemotherapy schedules and regimens
were specified according to protocol or selected by the
attending medical oncologists according to institutional stan-
dards. For radiotherapy, all patients underwent computed
tomography simulations and 3D-CRT treatment planning with a
commercial system (Pinnacle, Philips Medical Systems, An-
dover, MA) to deliver the prescribed dose of 45.0 to 50.4 Gy to
95% of the planning target volume. The definitions of clinical
target volume and planning target volume were the same as in
our earlier study.17 Heterogeneity correction was applied to all
dose calculations. Four or five fields were usually used in the
treatment plan, typically anterior-posterior angles in combina-
tion with oblique beams.
DVH Parameters
The DVH for total normal lung was computed from the
3D treatment plan. The total normal lung volume was defined
as the total lung volume minus the volumes of the trachea and
main bronchi. The following dosimetric parameters were
generated from the DVH: lung volume, mean lung dose, and
relative and absolute volumes of lung receiving more than a
threshold dose of radiation, for threshold doses ranging from
5 to 60 Gy in increments of 5 Gy.
Evaluation of TRP
Post-therapy, all patients were followed up every 3
months for the first 12 months and every 6 months thereafter
unless they had symptoms that required immediate examina-
tion or intervention. Chest radiograph or computed tomogra-
phy was performed at each follow-up. For this analysis, we
reviewed all relevant clinical notes dictated by the treating
physician and all radiographic images.
TRP was diagnosed by clinical presentation and any of
the following radiographic abnormalities: ground-glass opac-
ity, attenuation, or consolidation changes associated with
radiation fields within the first 12 months after radiotherapy.
TRP was graded according to the National Cancer Institute’s
Common Terminology Criteria for Adverse Events version
3.018 as follows: grade 1 disease was asymptomatic and
diagnosed by radiographic findings only, grade 2 disease was
symptomatic but did not interfere with daily activities, grade
3 disease was symptomatic and interfered with daily activities
or required administration of oxygen to the patient, grade 4
disease required assisted ventilation for the patient, and grade
5 disease was fatal.
Statistical Analysis
The end point for this analysis was the occurrence of
grade 2 TRP. Because TRP status was unknown for certain
patients with incomplete follow-up (e.g., because of death
from disease), statistical analyses were based on the time to
grade 2 TRP, measured from the end of radiotherapy.
Patients in whom grade 2 TRP was not observed were
censored at the date of last available follow-up. Kaplan-Meier
analysis was used to calculate freedom from TRP as a
function of time after the end of treatment, and the incidence
of TRP at a specified time point was calculated as 1 minus the
Kaplan-Meier estimate of freedom from TRP at that time
point. The log-rank test was used to perform univariate
analyses of differences in times to grade 2 TRP among
subsets of patients grouped by patient- (sex, age, smoking
history, chronic obstructive pulmonary disease, diabetes, and
Karnofsky performance status score), disease- (tumor loca-
tion and clinical stage), and treatment-related factors (radia-
tion dose or induction chemotherapy). A recursive partition-
ing technique based on the null Martingale residuals from the
Cox proportional hazards model19 was used to identify po-
tentially significant cut-points for DVH-derived dosimetric
parameters (the mean lung dose and the absolute and relative
lung volume spared or treated above doses of 5 to 60 Gy,
increments of 5 Gy).
RESULTS
Ninety-six consecutive patients treated at our institu-
tion met the inclusion criteria, and their demographic char-
acteristics are summarized in Table 1. Five-Fluorouracil (5-
FU) and its analogs were the primary chemotherapy agents
used; 5-FU and its analogs were administered to 82% of the
23 patients who received systemic chemotherapy before con-
current chemoradiation and to 94% of patients during con-
current chemotherapy. Among the 23 patients receiving sys-
temic chemotherapy before concurrent chemoradiation, 18
patients were enrolled onto various protocols in which the
induction chemotherapy was specified. An average of 2
cycles was used, and the number of courses of chemotherapy
received was 1 (n  1), 2 (n  15), 4 (n  3), 6 (n  1), 7
(n  2), or 11 (n  1). The systemic chemotherapy regimens
used are listed in Table 2. The 23 patients receiving systemic
chemotherapy before concurrent chemoradiation tended to
have advanced disease; 22 of them were stage III or IV. The
most common agents for concurrent chemotherapy were
5-FU plus cisplatin or 5-FU plus paclitaxel (Table 2).
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The median radiation dose was 50.4 Gy (range,
23.4 –64 Gy), and the median dose per fraction was 1.8 Gy
(range, 1.6 –3 Gy). The lung volumes ranged from 1937 to
7992 ml with a median 3700 ml. The mean lung dose
ranged from 4.0 to 33.4 Gy with a median of 13.6 Gy. The
median relative lung volume treated above 5,10, and 20 Gy
were rV5  59% (range, 12–94%), rV10  43% (range,
9 –81%), and rV20  23% (range, 6 –72%).
The median duration of follow-up was 8 months (range,
1–48 months). Twelve patients experienced grade 2 TRP,
three patients experienced grade 3 (one patient required
oxygen supplementation), and one experienced grade 5 TRP.
The incidence of grade 2 TRP was 16% at 6 months and
22% at 12 months in the entire patient cohort (Figure 1). The
patient who was considered to have had grade 5 TRP was a
70-year-old man with ultrasound stage T3N1 poorly differ-
entiated adenocarcinoma at the distal esophagus. He was
treated on a Radiotherapy Oncology Group trial with induc-
tion chemotherapy consisting of 2 cycles of cisplatin, 5-FU
and paclitaxol. He developed fever and respiratory problems
after induction chemotherapy and required oxygen supple-
mentation as home care. He then received concurrent chemo-
therapy with two cycles of 5-FU and paclitaxel, and radiation
therapy to 50.4 Gy at 1.8 Gy per fraction. He developed bilateral
lung, liver and adrenal metastases, pleural effusion, and bilateral
lower lung consolidation, in addition to progressive anemia and
TABLE 1. Demographic, Clinical, and Treatment
Characteristics and Their Association with Time to Grade
2 RP
Characteristic
Patients,
n (%)
Incidence of
TRP(%) at 12
mo (95% CI) pa
Age
67 yr 47 (49) 21 (11, 37) 0.846
67 yr 49 (51) 24 (12, 45)
Sex
Male 72 (75) 24 (14, 38) 0.396
Female 24 (25) 17 (6, 45)
Smoking history
Current smoker 18 (19) 11 (3, 38) 0.734
Quit smoking 55 (57) 23 (12, 41)
Never smoked 23 (24) 28 (13, 57)
Chronic obstructive pulmonary
disease
Yes 7 (7) 14 (2, 67) 0.805
No 89 (93) 23 (14,36)
Diabetes
Yes 17 (18) 34 (15, 66) 0.139
No 79 (82) 19 (11, 32)
Karnofsky performance status
90 47 (49) 13 (6, 30) 0.217
90 48 (50) 29 (17, 47)
Unknown 1 (1)
Tumor location
Cervical, upper thoracic, or
mid-thoracic
36 (38) 14 (5, 34) 0.258
Lower thoracic or GE
junction
60 (63) 27 (16, 44)
Clinical stage
I  II 22 (23) 17 (6, 45) 0.422
III  IV 74 (77) 24 (14, 38)
Induction chemotherapy
Yes 23 (24) 49 (26, 78) 0.003
No 73 (76) 14 (7, 27)
Radiation dose
50.4 Gy 16 (17) 14 (4, 47) 0.983
50.4 Gy 67 (70) 24 (14, 39)
50.4 Gy 13 (14) 15 (4, 49)
Mean lung dose
20 Gy 83 (86) 25 (15, 38) 0.319
20 Gy 13 (14) 8 (1, 43)
GE, gastroesophageal.
a Comparison of time to grade 2 RP and clinical and treatment variables among
subgroups. Patients with unavailable data are not included.
TABLE 2. Induction and Concurrent Chemotherapy
Regimens for the 96 Patients Treated with Concurrent
Chemoradiotherapy
Number
of
Patients
Induction Chemotherapy
Regimen
Concurrent
Chemotherapy Regimen
7 5-FU plus irinotecan and
docetaxel
5-FU plus irinotecan and
docetaxel
4 5-FU plus cisplatin and paclitaxel 5-FU plus paclitaxel
2 Cisplatin plus paclitaxel Cisplatin plus paclitaxel
1 UFT and LEUC plus carboplatin
and paclitaxel
5-FU plus irinotecan and
docetaxel
1 UFT and LEUC plus carboplatin
and paclitaxel
Cisplatin plus irinotecan
1 UFT and LEUC plus carboplatin
and paclitaxel
5-FU plus cisplatin
1 Carboplatin plus docetaxel and
irinotecan
5-FU plus paclitaxel
1 Cisplatin plus irinotecan 5-FU plus paclitaxel
1 Capecitabine plus carboplatin
and paclitaxel
5-FU plus paclitaxel
1 Capecitabine plus carboplatin
and paclitaxel
5-FU plus cisplatin
1 Capecitabine plus carboplatin
and paclitaxel
Carboplatin plus paclitaxel
1 Capecitabine plus carboplatin
and docetaxel
5-FU plus paclitaxel
1 5-FU plus cisplatin 5-FU plus cisplatin
18 5-FU plus paclitaxel
1 Cisplatin plus paclitaxel
8 5-FU
6 5-FU plus carboplatin
5 5-FU plus carboplatin and
paclitaxel
2 5-FU plus docetaxel
26 5-FU plus cisplatin
4 Capecitabine plus paclitaxel
1 Capecitabine plus cisplatin
1 Capecitabine
1 Irinotecan
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diarrhea caused by clostridium difficile infection, and required
multiple hospitalizations. He eventually developed acute pro-
gressive respiratory distress, which was felt to be a result of the
combined effect of pneumonia and TRP.
Table 1 shows the association between patient-, dis-
ease-, and treatment-related variables and time to grade 2
TRP. The drugs used and the number of courses of systemic
chemotherapy were not associated with the risk of TRP.
Importantly, there was no difference in TRP between the
patients who received 1 to 2 cycles, compared with those who
received 4 to 11 cycles (p  0.906, log-rank test): The only
statistically significant clinical factor was use of systemic
chemotherapy before concurrent chemoradiation. The 1-year
incidence of grade 2 TRP was 49% for patients who had
undergone upfront systemic chemotherapy and 14% for those
who had not, respectively (Figure 2; p  0.003). There was
no significant difference in time to grade2 TRP for patients
subdivided by any other factors investigated. Furthermore,
none of the dosimetric factors derived from the DVH was
found to be significantly associated with time to grade 2
TRP.
There were no significant differences in the distribu-
tions of mean lung dose and V5 through V60 (in increments
of 5 Gy, i.e., V5, V10, V15, etc.) for the groups of patients
receiving upfront systemic chemotherapy or concurrent che-
motherapy alone (p  0.20 in every case). There was no
difference in the percentages of patients with mean lung dose
20 Gy in the upfront systemic chemotherapy and concur-
rent chemotherapy alone groups (p  0.19).
DISCUSSION
To our knowledge, this retrospective study was the first
one focusing on possible risk factors associated with TRP
among esophageal cancer patients treated with definitive
chemoradiation. In this study, 22% of patients developed
grade 2 RP at 1 year, an incidence lower than that in
patients who were treated for lung cancer in a previous study
from our group.20 The incidence of high grade TRP (grade
3) was rare in this population compared with lung cancer
patients who were treated with concurrent chemoradiation.
Nevertheless, there were two major differences between the
study populations of the current study and the one of non-
small cell lung cancer (NSCLC) from our group: firstly,
patients in the current study with esophageal cancer typically
had healthy lungs and good pulmonary function, whereas the
patients in the NSCLC study had a tumor in the lung and
usually poor lung function. Secondly, the radiation dose is
moderate in the current study and quite high in the NSCLC
study. We believe these differences might explain the differ-
ences in the incidence of TRP between the two populations.
The differences in baseline physiological status of lung and in
radiation dose might also explain the fact that, in contrast to
published reports on lung cancer patients, upfront systemic
chemotherapy was the only factor that was significantly
associated with time to occurrence of Common Toxicity
Criteria 3.0 grade 2 TRP in the present esophageal cancer
population, with no association found for dosimetric factors.
The 1-year incidences of grade 2 RP were 49% and 14% in
the groups that received upfront systemic chemotherapy and
that did not, respectively (p  0.003). The standard radiation
dose for esophageal cancer is 50.4 Gy, a dose that rarely
causes any symptomatic TRP if used alone, according to our
clinical experience. Nevertheless, when combined with che-
motherapy, the effect of radiation to normal tissue will be
altered and most probably intensified.
One should note that in our previous study with esoph-
ageal cancer patients, induction chemotherapy was not asso-
ciated with an increased risk of postoperative acute respira-
tory distress syndrome or pneumonia. Nevertheless, one
should keep in mind that the treatment and end point of our
earlier study were different from those of current study: all
patients had surgery, and the end point was postoperative
pulmonary complication, which is not TRP. There has been a
lack of literature addressing the association between chemo-
therapy and TRP in patients with esophageal cancer treated
with chemoradiation, an indication of a field that has been
under studied. The results on the same topic from other
disease sites, however, could perhaps shed some light on this
subject. There is evidence that chemotherapy drugs cause
FIGURE 1. Freedom from grade 2 TRP as a function of
time from the end of radiotherapy among 96 esophageal
cancer patients treated with definitive chemoradiotherapy.
Curves were calculated using the method of Kaplan and
Meier.
FIGURE 2. Effect of systemic chemotherapy before concur-
rent chemoradiation on freedom from grade 2 TRP.
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functional damage, and hence reduced radiation tolerance of
the lung to radiation, in breast cancer patients who, like
esophageal cancer patients, have generally healthy lungs.21–23
In breast cancer patients who received paclitaxel as part of
their chemotherapy regimen, a reduction of approximately
24% in effective lung tolerance was reported.21 It has also
been reported22 that, after 3 cycles of induction cyclophos-
phamide, doxorubicin, and 5-FU chemotherapy in breast
cancer, the mean diffusing capacity of the lungs for carbon
monoxide (DLCO) decreased significantly by 12.6%. Fur-
thermore, bronchoalveolar lavage has demonstrated signifi-
cant elevations in interleukin-6, interleukin-8, neutrophils,
and lymphocytes. These results suggest that induction che-
motherapy can induce asymptomatic pulmonary dysfunction
and inflammation that may prime the lungs for injury during
radiotherapy and predispose the lungs to the development of
delayed pulmonary toxicity syndrome.22 In another study,
Lind et al.23 also found that, after chemotherapy, there were
marked reductions in lung function at the time of radiation
compared with baseline in breast cancer patients. The ratio of
preradiotherapy DLCO to the minimum postchemotherapy
DLCO, i.e., the trend of improvement, predicted the devel-
opment of radiation pneumonitis, suggesting that a delay of
the start of radiation might allow sufficient functional recov-
ery of the lung from chemotherapy to avoid radiation pneu-
monitis.23 In patients with Hodgkin disease or small cell lung
cancer, adriamycin-containing chemotherapy regimens were
associated with a higher incidence of radiation lung damage
detected by computed tomography compared with nonadria-
mycin containing chemotherapy regimens. The addition of
adriamycin, bleomycin, vincristine, and DTIC or cyclophosph-
amide, adriamycin, and vincristine reduced the tolerance of lung
to radiation.24 An association between chemotherapy and the
risk of TRP in patients with lung cancer has also been reported,
though there are inconsistencies among the reported studies.
Some studies found an increased risk of radiation pneumonitis
after chemotherapy or concurrent chemotherapy,25,26 whereas
others showed no increased risk.2,6,27,28 For example, Mao re-
cently reported that in lung cancer patients the use of induction
chemotherapy before radiotherapy increased the rate of radia-
tion-induced pneumonitis.29 Gopal et al.25 reported that the
addition of chemotherapy to radiotherapy significantly exacer-
bated the postradiotherapy decrease in lung function. The great-
est decrease in lung function occurred in patients treated with
concurrent chemoradiation. Lee et al.26 reported that grade 3
lung toxicity was significantly more common among lung can-
cer patients who received induction plus concurrent cisplatin-
based chemotherapy with conventional radiotherapy (21%) or
concurrent chemotherapy with hyperfractionated radiotherapy
(20%) than among those who received only induction chemo-
therapy before conventional radiotherapy (10%). A retrospective
analysis of lung cancer treated with concurrent chemoradiother-
apy showed that the incidence of grade  2 radiation pneumo-
nitis patients who received irinotecan (56%) was higher than
those who did not (14%).30 The findings from this study are
consistent with the results from studies discussed above, though
in our study there was no difference in the risk of TRP by
chemotherapy drugs or number of cycles given.
In this study, the radiation dosimetric factors were not
associated with the time to occurrence of grade 2 TRP, in
contrast to what was found for patients with NSCLC from our
own and other studies.1–8,20 The median mean lung dose was
13.6 Gy for this group of patients compared with 22.4 Gy in
lung cancer patients treated during the same period in our
institution.20 It is speculated that the lack of association
between radiation dosimetric factors and risk of TRP in this
study was the result of the lower radiation dose used (50.4
Gy) for esophageal cancer treatment compared with the doses
used for NSCLC (60–70 Gy). When radiation dose is high
enough to cause symptomatic pneumonitis on its own, the
dosimetric factors predominated the effect of other clinical
and treatment-related factors in the development of TRP.
This speculation is supported by a study of Taghian et al.31
that found, in breast cancer patients who received radiation
and sequential or concurrent paclitaxel-contained chemother-
apy, that the mean percentage of lung volume irradiated was
20% in patients who developed TRP and 22% in those who
did not (p  0.6), suggesting that when chemotherapy was
used, reduction in the volume of the lung irradiated does not
necessarily offset the risk of TRP.
The current study included a group of relative homo-
geneous patients in their patient-, disease-, and radiation
treatment-related characteristics. Nevertheless, one need rec-
ognize that the current study was a retrospective review of
our institution’s experience with a small number of patients,
and it had the inherent shortcomings of a retrospective trial,
such as patient selection bias, inconsistency in chemotherapy
drugs, number of cycles of chemotherapy given, patients
receiving systemic chemotherapy before concurrent chemo-
radiation tending to have advanced disease, etc. Nonetheless,
we believe that the results from the current study are important
and supported by results from TRP studies of other disease sites.
The association between systemic chemotherapy and risk of
TRP in esophageal cancer patients treated with combined che-
moradiation needs to be investigated and the mechanism under-
stood for the sake of patient safety. When the role of systemic
chemotherapy on TRP is prospectively confirmed, pulmonary
function tests should be compared.
In summary, we found that use of upfront systemic che-
motherapy before concurrent chemoradiation in the treatment of
esophageal cancer was associated with an increased incidence of
TRP. A future clinical trial with adequate numbers of patients is
warranted to further evaluate the risk factors for TRP in esoph-
ageal cancer patients, especially the potentially additive toxic
effects of combined treatment modalities.
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